National Academy of Sciences | 150 Year Anniversary

Questions? Call 800-624-6242

| Items in cart [0]

The National Academies Press

PAPERBACK
price:$43.00
add to cart

Rights & Permissions

topleft topright

Reaping the Benefits of Genomic and Proteomic Research: Intellectual Property Rights, Innovation, and Public Health (2006)
Board on Science, Technology, and Economic Policy (STEP)

Citation Manager

. "4 Trends in the Patenting and Licensing of Genomic and Protein Inventions and Their Impact on Biomedical Research." Reaping the Benefits of Genomic and Proteomic Research: Intellectual Property Rights, Innovation, and Public Health. Washington, DC: The National Academies Press, 2006.

Please select a format:

BibTeX EndNote RefMan


Page
116
bottomleft bottomright

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.


Reaping the Benefits of Genomic and Proteomic Research: Intellectual Property Rights, Innovation, and Public Health

 

Total Patents

Top Assignees

Algorithms

91

Cytokinetics (42) All others (2 or 1)

Databases

1,466

Affymetrix (108)

U. California (45)

Agilent Tech. (34)

Nanogen (22)

Sequenom (18)

EGF

765

Sugen (23)

Genentech (16)

U. California (12)

DHHS (12)

Yale (11)

CTLA4

63

Bristol-Myers Squibb (20)

Dana Farber (6)

Repligen (4)

Genetics Inst. Inc. (3)

Pfizer (3)

NF-kB

94

U. California (7)

Bristol-Myers Squibb (6)

Tularik (5)

Ariad (3)

Dalhousie Univ. (3)

NOTE: The assignee is the company or organization assigned ownership on the original patent. Through consolidations, mergers and acquisitions, and other transactions, ownership may change. Private organizations, foundations, and hospitals are distinguished from commercial entities by italics. Government entities are indicated by bold typeface.

TRENDS IN UNIVERSITY LICENSING OF GENOMIC AND PROTEOMIC INVENTIONS

Licensing is the principal means of accessing the use of patented technology, and it occurs under terms that are infinitely varied and complex and whose effects are not straightforward. Thus, whether a patented upstream invention is available for licensing—and under what conditions—is possibly the principal determinant of whether exclusive rights can impede or alternatively, facilitate the conduct of follow-on research. Unfortunately, data on licensing are very limited for two reasons. First, unlike patents, government administrative processes generate information on only some licenses whose representativeness is unknown and for which detailed information may be lacking and not publicly available. Licenses to or by

Page
116